文献速递膀胱癌与上尿路尿路上皮癌

膀胱内溶瘤病毒治疗与免疫治疗对非肌层浸润性膀胱癌小鼠模型的作用

Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model.
PubMed 文献 · BJU Int · 2023-04-04

在MBT2原位同系C3H小鼠膀胱癌模型中,比较膀胱内灌注抗PD-1抗体、溶瘤呼肠孤病毒或两者联合与不治疗的疗效。单次灌注后,三组治疗组中位总生存均未达到,对照组中位生存41天,联合组与单药组间无显著差异。CD8+ T细胞清除消除了生存优势。

要点

  • 单次膀胱内灌注抗PD-1、呼肠孤病毒或联合均较不治疗改善生存。
  • 抗PD-1单药与呼肠孤病毒单药生存无显著差异(P=0.067)。
  • 联合治疗富集单核细胞、减少髓源性抑制细胞,CD8+ T细胞介导生存获益。

核心结论

  • 小鼠原位膀胱肿瘤单次膀胱内灌注呼肠孤病毒、抗PD-1抗体或联合均较对照获得更优生存。
  • 肿瘤免疫微环境差异提示髓源性抑制细胞和CD8+ T细胞介导治疗反应。

研究设计与样本

  • 采用MBT2尿路上皮膀胱癌原位同系C3H小鼠模型,每组10只,比较不治疗、膀胱内抗PD-1、膀胱内溶瘤呼肠孤病毒、膀胱内呼肠孤病毒+抗PD-1四组,单次膀胱内治疗。
  • 主要结局为总生存,次要结局包括长期免疫和肿瘤免疫谱。

主要发现

  • 中位随访9个月,不治疗组全部死亡,中位生存41天;呼肠孤病毒组中位总生存未达到(HR 14.4,95%CI 3.9-32.6;P<0.001)。
  • 抗PD-1组中位总生存未达到(HR 28.4,95%CI 7.0-115.9;P<0.001);呼肠孤病毒+抗PD-1组中位总生存未达到(HR 28.4,95%CI 7.0-115.9;P<0.001)。
  • 抗PD-1单药与呼肠孤病毒单药生存无显著差异(P=0.067)。
  • 质谱流式显示呼肠孤病毒+抗PD-1治疗富集单核细胞并减少髓源性抑制细胞,形成免疫应答性肿瘤微环境。
  • 清除CD8+ T细胞消除了膀胱内治疗带来的生存优势。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To test if intravesical instillation of both an anti-programmed cell death protein 1 (PD-1) inhibitor and an oncolytic reovirus would demonstrate a greater effect than either treatment alone, as non-muscle-invasive bladder cancer that is refractory to intravesical bacillus Calmette-Guérin can be treated by systemic anti-PD-1 immunotherapy and we previously demonstrated improved overall survival (OS) with six once-weekly instillations of intravesical anti-PD-1 in a murine model. MATERIALS AND METHODS: Using an orthotopic syngeneic C3H murine model of MBT2 urothelial bladder cancer, groups of 10 mice were compared between no treatment, intravesical anti-PD-1, intravesical oncolytic reovirus, or intravesical reovirus + anti-PD-1. A single intravesical treatment session was given. The primary outcome was OS, and the secondary outcomes included long-term immunity and tumour-immune profile. RESULTS: With a median follow-up of 9 months, all mice that received no treatment died with a median survival of 41 days, while the comparison median OS was not reached for reovirus (hazard ratio [HR] 14.4, 95% confidence interval [CI] 3.9-32.6; P < 0.001), anti-PD-1 (HR 28.4, 95% CI 7.0-115.9; P < 0.001), and reovirus + anti-PD-1 (HR 28.4, 95% CI 7.0-115.9; P < 0.001). Monotherapy with anti-PD-1 or reovirus demonstrated no significant differences in survival (P = 0.067). Mass cytometry showed that reovirus + anti-PD-1 treatment enriched monocytes and decreased myeloid-derived suppressor cells, generating an immuno-responsive tumour microenvironment. Depletion of CD8+ T cells eliminated the survival advantage provided by the intravesical treatment. CONCLUSIONS: Treatment of murine orthotopic bladder tumours with a single instillation of intravesical reovirus, anti-PD-1 antibody, or the combination confers superior survival compared to controls. Tumour-immune microenvironment differences indicated myeloid-derived suppressor cells and CD8+ T cells mediate the treatment response.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Smelser WW, Wang J, Ogden KM, et al. Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model. BJU Int. 2023. PMID: 36961272. doi:10.1111/bju.16012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。